
JB Chemical’s (JBCP) has entered into Trade Mark License agreement with Novartis Innovative Therapies AG, beginning Jan’27, for a portfolio of 10 opthalmic brands in Indian market. Initially the company will in-license all 10 brands (generic in nature) from Novartis for a period of 3 years starting Dec’23 for Rs 1.25bn and later acquire all 10 brands for a consideration of $116mn (Rs 9.64bn) payable on or before 31st Dec26
Recent Comments